To better understand the mechanism of resistance to gefitinib in EGFR-mutated NSCLC cells, we aimed to determine how DARPP-32 activates ERBB3 signaling to suppress gefitinib-mediated EGFR inhibition. This evidence concerns the gene PPP1R1B and non-small cell lung carcinoma.